SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
Last trade$1.67
Day change+$0.095 (+6.03%)
Day range$1.52 – $1.68
Volume21,037
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.7M
Price / earnings
—
Price / book
0.44×
Price / sales
102.52×
EV / sales
-66.35×
EV / EBITDA
0.53×
Profitability
Earnings per share
-$1.59
Return on assets
-42.29%
Return on equity
-44.05%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
24.43×
Quick ratio
24.43×
Cash ratio
17.32×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SILO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$18.03K
$18.03K
$18.03K
$18.03K
$18.03K
$18.03K
Cost of revenue
$0
$0
$20.69K
$20.69K
$20.69K
$1.46K
$1.46K
$1.46K
Gross profit
$0
$0
-$2.66K
-$2.66K
-$2.66K
$16.57K
$16.57K
$16.57K
Selling, general and administrative
$649.55K
$630.53K
$578.73K
$401.42K
$605.19K
$547.87K
$516.73K
$694.1K
Research and development
$559.09K
$298.42K
$1.01M
$306.01K
$543.62K
$717.25K
$593.96K
$1.08M
Total operating expenses
$1.21M
$928.95K
$1.59M
$783.86K
$1.15M
$1.27M
$1.11M
$1.83M
Operating income
-$1.21M
-$928.95K
-$1.59M
-$786.52K
-$1.15M
-$1.25M
-$1.09M
-$1.81M
Interest expense
-$1.11K
-$2.87K
-$3.37K
-$32.7K
-$886
-$1.65K
-$2.07K
-$274
Income before taxes
-$358.74K
-$832.83K
-$1.65M
-$881.53K
-$1.11M
-$1.2M
-$1.03M
-$1.73M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$358.74K
-$832.83K
-$1.65M
-$881.53K
-$1.11M
-$1.2M
-$1.03M
-$1.73M
Net income attributable to common shareholders
-$358.74K
-$832.83K
-$1.65M
-$881.53K
-$1.11M
-$1.2M
-$1.03M
-$1.73M
EBITDA
-$1.2M
-$931.89K
-$1.59M
-$783.59K
-$1.14M
-$1.25M
-$1.09M
-$1.81M
Basic earnings per share
-$0.21
-$0.76
-$0.12
-$0.05
-$1.79
-$2.88
-$0.23
-$0.38
Diluted earnings per share
-$0.21
-$0.76
-$0.12
-$0.05
-$1.79
-$2.88
-$0.23
-$0.38
Recent news
Company coverage with links to the original publishers.
Silo Pharma's subsidiary QwikAgents has partnered with Caylent, an AWS Premier Tier Services Partner, to build a new AWS-native platform. The collaboration aims to enhance scalability, performance, and security for enterprise deployment, with expected funding support from AWS and Caylent to accelerate commercialization and product innovation.
Silo Pharma announced progress on two strategic fronts: its QwikAgents AI subsidiary is preparing for commercial launch within 60-90 days to generate initial revenue in the enterprise AI market, while its lead PTSD therapeutic candidate SPC-15 advances through regulatory milestones including completion of a drug-device robustness study and preparation for an FDA Type C meeting. The company recently raised capital through a private placement to support these initiatives.
Silo Pharma announced that its subsidiary QwikAgents has been accepted into Advanced Micro Devices' AMD AI Developer Program. The acceptance provides access to AMD Developer Cloud credits, AI development tools, and technical resources to support QwikAgents' next-generation AI agent platform designed for individuals, developers, small businesses, and enterprises.
U.S. stock futures rose on Tuesday as investors awaited Trump's deadline regarding Iran's Strait of Hormuz. UnitedHealth Group surged 6.86% following favorable Medicare Advantage payment rates, while Silo Pharma jumped 45.31% on a patent approval for PTSD treatment. Phillips 66 declined 0.75% due to reported losses from rising oil prices amid geopolitical tensions. The S&P 500 and Nasdaq Composite posted modest gains, with analysts maintaining optimistic outlooks for 2026 despite ongoing market volatility.
Silo Pharma has initiated a strategic partnership with Fireblocks to develop an institutional-grade infrastructure for managing digital assets, leveraging Fireblocks' secure digital asset custody and transfer capabilities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.